( stases (the type of liver metastases se...)The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer,Health

About Eloxatin(R)

Indications and Usage

Eloxatin, used in combination with infusional 5-FU/LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor. The indication is based on an improvement in disease-free survival, with no demonstrated benefit in overall survival after a median follow up of 4 years.

ELOXATIN, used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum.

Clinical Safety Considerations

Eloxatin(R) should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents.

Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.

Anaphylactic-like reactions to Eloxatin(R) have been reported and may occur within minutes of Eloxatin(R) administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms, and discontinuation of Eloxatin(R) therapy may be required.

    * Eloxatin(R) should not be administered to patients with a history of

      known allergy to Eloxatin(R) or other platinum compounds.

      Hypersensitivity and anaphylactic/anaphylactoid reactions to

      Eloxatin(R) have been reported and were similar in nature and severity

      to those reported with other platinum compounds (ie, rash, urticaria,

      erythema, pruritus, and, rarely, bronchospasm and hypotension). These

      reactions occur within minutes of administration and should be managed

      with appropriate supportive therapy. Drug-related deaths from this

      reaction have been reported


    * Eloxatin(R) may cause fetal harm when administered to a pregnant woman.

      Women of childbearin
'"/>




Page: 1 2 3 4 5 6 7 8 9 
Related medicine technology :

1. MabThera Significantly Increases Survival of Lymphoma Patients
Regardless of Chemotherapy Regimen
2. Data Presented at AACR Meeting Show Peregrines Bavituximab
Equivalent Can Generate Curative Immune Responses as Part of a
Vaccine-Like Regimen in Preclinical Models of Aggressive Brain
Cancer
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking
Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure
Than Ibuprofen in Osteoarthritis Patients with Controlled
Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood
Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled
Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid
Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace
Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in
Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly
Improved Migraine Pain on Several Efficacy Measures in a Phase II
Study
10. Nexavar Significantly Extends Overall Survival by 44% in Liver
Cancer Patients
11. MabThera Significantly Extends Survival And Cures More Patients
With Aggressive Lymphoma Than Chemotherapy Alone